Halvard Gjønnæss Fertility and Sterility

Slides:

Advertisements

Similar presentations

JAN WHITEFIELD UTERINE BLEEDING CASE PRESENTATION OF A BLEEDING WOMAN IN REMOTE ALASKA.

Advertisements

Human Endocrine Physiology February 27, 2014.

Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome Madelon van Wely, Ph.D.,

Clinically significant and sustained weight loss is achievable in obese women with polycystic ovary syndrome followed in a regular medical practice Lysanne.

Andrew J. Krentz, M.D., Elizabeth Barrett-Connor, M.D.

Evaluation and Management of Amenorrhea

Yuqian Cui, M. D. , Ph. D. , Yuhua Shi, M. D. , Ph. D. , Linlin Cui, M

A new ultrasound criterion for the diagnosis of polycystic ovary syndrome: the ovarian stroma/total area ratio Anna Maria Fulghesu, M.D., Mario Ciampelli,

Hatem Abu Hashim Reproductive BioMedicine Online

Endocrine and cardiometabolic cord blood characteristics of offspring born to mothers with and without polycystic ovary syndrome Nadine M.P. Daan, M.D.,

The antiandrogenic effect of flutamide improves uterine perfusion in women with polycystic ovary syndrome Silvia Ajossa, M.D., Stefano Guerriero, M.D.,

Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study Thi.

Increased prevalence of anxiety symptoms in women with polycystic ovary syndrome: systematic review and meta-analysis Anuja Dokras, M.D., Ph.D., Shari.

Comparison of hormonal and metabolic markers after a high-fat, Western meal versus a low-fat, high-fiber meal in women with polycystic ovary syndrome

Risk of obstructive sleep apnea in obese and nonobese women with polycystic ovary syndrome and healthy reproductively normal women Babak Mokhlesi, M.D.,

Suppression and recovery of gonadotropin and steroid secretion by a gonadotropin- releasing hormone receptor antagonist in healthy women with normal ovulation.

Ovarian size and blood flow in women with polycystic ovary syndrome and their correlations with endocrine parameters Enrico Carmina, M.D., Francesco.

Plasminogen activator inhibitor 1 and miscarriage after metformin treatment and laparoscopic ovarian drilling in patients with polycystic ovary syndrome

Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic.

Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot.

A randomized controlled study comparing the endocrine effects of pulsatile intravenous gonadotropin-releasing hormone after gonadotropin-releasing hormone.

Risk of depression and other mental health disorders in women with polycystic ovary syndrome: a longitudinal study Angela Kerchner, B.A., Whitney Lester,

Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels

Differential lipopolysaccharide (LPS)-stimulated TNFα release from mononuclear cells (MNC) of normal weight vs. obese women with polycystic ovary syndrome.

Rebecca A. Feldman, M. D. , Kathleen O'Neill, M. D. , Samantha F

Efficacy of metformin therapy in adolescent girls with androgen excess: relation to sex hormone–binding globulin and androgen receptor polymorphisms

Effect of N-acetyl-cysteine after ovarian drilling in clomiphene citrate-resistant PCOS women: a pilot study A. Nasr Reproductive BioMedicine Online

Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular.

Epidemiology and Adverse Cardiovascular Disease (CVD) Risk Profile of Polycystic Ovarian Syndrome (PCOS): The Kaiser Permanente Polycystic Ovarian Syndrome.

High-molecular-weight adiponectin is inversely associated with sympathetic activity in polycystic ovary syndrome Soulmaz Shorakae, M.D., Sally K. Abell,

Serum soluble leptin receptor levels and free leptin index in women with polycystic ovary syndrome: relationship to insulin resistance and androgens

Clinical Assessment of Recombinant Human Follicle-Stimulating Hormone in Stimulating Ovarian Follicular Development Before In Vitro Fertilization fn1

Serum luteinizing hormone levels are markedly increased and significantly correlated with Δ4-androstenedione levels in lean women with polycystic ovary.

Hyperglycemia Stimulates Activation of Nuclear Factor κB (NFκB) in Mononuclear Cells (MNC) of Women With Polycystic Ovary Syndrome (PCOS) F. Gonzalez,

Fertility and Sterility

Role of insulin in the hyperandrogenemia of lean women with polycystic ovary syndrome and normal insulin sensitivity Jean-Patrice Baillargeon, M.D.,

Effects of laparoscopic ovarian drilling on serum vascular endothelial growth factor and on insulin responses to the oral glucose tolerance test in women.

Increased secretion of amylin in women with polycystic ovary syndrome

Correlations between concentrations of interleukin-12 and interleukin-13 and lymphocyte subsets in the follicular fluid of women with and without polycystic.

Relationship between sleep and secretion of gonadotropin and ovarian hormones in women with normal cycles Sandrine Touzet, M.D., Muriel Rabilloud, M.D.,

Mean versus individual hormonal profiles in the menstrual cycle

Fleur R. Cattrall, M. B. B. S. , Beverley J. Vollenhoven, M. B. B. S

Relationship between insulin resistance and gonadotropin dissociation in obese and nonobese women with polycystic ovary syndrome Carlos Moran, M.D.,

A retrospective study on the use of dose-dependent letrozole to decrease cancer recurrence and adverse events in patients undergoing ovarian stimulation

Evidence for competing effects of body mass, hyperinsulinemia, insulin resistance, and androgens on leptin levels among lean, overweight, and obese women.

Effects of metformin on body mass index, menstrual cyclicity, and ovulation induction in women with polycystic ovary syndrome Derek A Haas, M.D., Bruce.

Impact of laparoscopic ovarian drilling on anti-Müllerian hormone levels and ovarian stromal blood flow using three-dimensional power Doppler in women.

Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin Samuel S. Thatcher, M.D., Ph.D., Elizabeth M.

Postprandial triglyceride response in patients with polycystic ovary syndrome: relationship with waist-to-hip ratio and insulin Elsy Velázquez M, M.D.,

Thilo Schill, M. D. , Monika Bals-Pratsch, M. D. , Wolfgang Küpker, M

Paolo Moghetti, M.D. Fertility and Sterility

Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome Madelon van Wely, Ph.D.,

Are patients with idiopathic hirsutism (IH) insulin resistant

Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal-weight normoinsulinemic women with polycystic ovary syndrome:

Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction and achievement of pregnancy in 154 women with.

Increased total and phosphorylated glycogen synthase kinase-3 (GSK-3) in the adipocytes of patients with the polycystic ovary syndrome (PCOS) W.Y. Chang,

Follicle-stimulating hormone receptor gene mutations are rare in Japanese women with premature ovarian failure and polycystic ovary syndrome Kenji Takakura,

Inappropriate gonadotropin secretion in polycystic ovary syndrome

Operative transvaginal hydrolaparoscopy for treatment of polycystic ovary syndrome: a new minimally invasive surgery Hervé Fernandez, M.D., Jean-Dominique.

Tsan-Hon Liou, M. D. , Ph. D. , Jen-Hung Yang, M. D. , Ph. D

Effect of long-term naltrexone treatment on endocrine profile, clinical features, and insulin sensitivity in obese women with polycystic ovary syndrome

Follicle-stimulating hormone receptor polymorphisms in women with normogonadotropic anovulatory infertility Joop S.E Laven, Ph.D., Annemarie G.M.G.J.

Transforming growth factor-β1 and its receptor soluble endoglin are altered in polycystic ovary syndrome during controlled ovarian stimulation Reshef.

Cardiovascular and metabolic profiles amongst different polycystic ovary syndrome phenotypes: who is really at risk? Nadine M.P. Daan, M.D., Yvonne V.

Increased risk of depressive disorders in women with polycystic ovary syndrome Elizabeth Hollinrake, B.S., Alison Abreu, M.D., Michelle Maifeld, R.N.C.,

Relation of intra-abdominal fat distribution to metabolic disorders in nonobese patients with polycystic ovary syndrome Basak Yildirim, M.D., Nuran Sabir,

Adolescent girls with polycystic ovary syndrome showing different phenotypes have a different metabolic profile associated with increasing androgen levels

Stephen J Winters, M. D. , Evelyn Talbott, David S Guzick, Ph. D. , M

Advanced oxidation protein products are increased in women with polycystic ovary syndrome: relationship with traditional and nontraditional cardiovascular.

Enrico Carmina, M.D., Rogerio A Lobo, M.D. Fertility and Sterility

Presentation transcript:

Late Endocrine Effects of Ovarian Electrocautery in Women with Polycystic Ovary Syndrome Halvard Gjønnæss Fertility and Sterility Volume 69, Issue 4, Pages 697-701 (April 1998) DOI: 10.1016/S0015-0282(98)00006-5

Fig. 1 Pituitary hormones and SHBG after ovarian electrocautery in patients with PCOS. Data show mean values and −1 SD before electrocautery (column 1, n = 51) and after 3 months (column 2,n = 46 + one pregnant), 1 year (column 3,n = 47), 3 years (column 4, n = 48), 10 years (column 5, n = 42), 10–18 years (column 6,n = 31), and >18 years (column 7, n = 15). Units of measure are as follows: LH and FSH, IU/L; prolactin, mIU/L; SHBG; nmol/L. ∗∗∗P < 0.001, ∗∗P < 0.01, ∗P < 0.05, versus preoperative values. Fertility and Sterility 1998 69, 697-701DOI: (10.1016/S0015-0282(98)00006-5)

Fig. 2 Ovarian hormones after ovarian electrocautery in patients with PCOS. E2 = estradiol; E1 = estrone. For details, see text to Fig. 1. Fertility and Sterility 1998 69, 697-701DOI: (10.1016/S0015-0282(98)00006-5)

Fig. 3 Androgen levels after ovarian electrocautery in patients with PCOS. DHT = dihydrotestosterone. For details, see text to Fig. 1. Fertility and Sterility 1998 69, 697-701DOI: (10.1016/S0015-0282(98)00006-5)